Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
In a 40-week Phase 3 trial, adults with type 2 diabetes taking 12 mg of retatrutide shed an average of 16.8% (36.6 lbs) of their beginning weight
The MHRA has licensed several GLP-1 agonists for use in the UK, and NICE guidelines (NG28) recommend them for specific patient groups, particularly those with type 2 diabetes who have not achieved adequate control with other medications or who have additional cardiovascular risk factors
Retatrutide appears to push the boundaries further with its third receptor target
According to research published in the New England Journal of Medicine, patients using Tirzepatide achieved body weight reductions exceeding 20% in some study groups
.png?sfvrsn=1e7191c0_3)
US$ 27.77
US$ 24.74
US$ 20.46
